GET DAILY SIGNALSAbsci Corporation (ABSI) Could See +55% Upside if It Hits the $15 Analyst Target
Key Takeaways
- The $15 central target is the arithmetic mean of roughly a dozen verified analyst price targets (rounded from approximately $14.50), with individual targets spanning a wide $10 to $20 range.
- With Absci Corporation (ABSI) recently trading near $9.67, reaching $15 would require upside of roughly 55% — a substantial move.
- The wide target range reflects genuine disagreement about how much an early-stage, AI-driven drug pipeline is worth before clinical proof of concept.
- Strongest supports include positive interim Phase 1 data for lead candidate ABS-201, fresh capital from Eli Lilly and AMD, and a series of 2026 target increases and upgrades.
- Biggest risks are the absence of human efficacy data, persistent losses and cash burn, a rich valuation, and binary clinical readouts.
- For more on ABSI, explore its Major News, Today's Price Move, Forecast, and Earnings pages.
- Interested in AI-driven market signals? Explore Trending AI Robots for automated trading insights.
Breaking Down the Analyst Consensus
Absci Corporation (ABSI) is a clinical-stage biopharmaceutical company that uses a generative-AI "Integrated Drug Creation" platform to design antibody therapeutics. Its analyst coverage skews heavily bullish, with the large majority of firms rating the shares Buy, Overweight, or Outperform and only a handful at Hold.
Verified individual targets reviewed include $20 from KeyBanc (October 2026), $17 from Truist, $16 from H.C. Wainwright and BTIG, $15 from J.P. Morgan and Guggenheim, $14 from Jefferies (initiation), $13 from JonesTrading, $12 from Leerink Partners, $11 from Needham, and $10 from Morgan Stanley. Averaging these yields a mean near $14.50, which rounds to the $15 central target used here. The low-to-high range of roughly $10 to $20 is unusually wide, underscoring how sensitive these estimates are to assumptions about pipeline value.
Bullish analysts emphasize positive interim Phase 1 safety and pharmacokinetic data for ABS-201, its lead candidate for androgenetic alopecia (hair loss) and endometriosis, plus the de-risking effect of a $100 million equity offering in which Eli Lilly participated. More cautious voices, such as Morgan Stanley's $10 Hold target, reflect that the pipeline has not yet produced human proof of concept. These are analyst expectations, not guarantees. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Where ABSI Stands Today
ABSI has been highly volatile, moving within a 52-week range of roughly $2.24 to $12.55 and recently trading near $9.67 after a prior close near $10.12. Reaching the $15 target implies upside of about 55%, a substantial move for a company that remains unprofitable.
The path would likely depend on clinical execution rather than current fundamentals. Revenue is minimal — roughly $215,000 in the most recent reported quarter — and the company reports a negative EPS while funding a growing research organization. Any sustained move toward $15 would most plausibly be driven by positive data from Phase 1 or Phase 2 readouts for ABS-201 and ABS-101, progress on partnerships, or renewed enthusiasm for AI-enabled drug discovery, rather than near-term earnings.
Factors That Could Drive Gains
- Clinical momentum: Favorable interim Phase 1 data for ABS-201 and expansion into new indications such as endometriosis have driven much of the stock's 2026 advance.
- Strategic and financial backing: A $100 million placement with Eli Lilly participation and a $20 million PIPE investment from AMD have improved the cash runway and platform credibility.
- Analyst revisions: Several firms raised targets in 2026, including KeyBanc to $20, J.P. Morgan to $15, and Truist to $17, reflecting improving conviction after data releases.
- Sector momentum: Renewed investor interest in AI-driven drug discovery has supported valuations across the space.
Key Risks to Watch
- No proof of concept: ABS-201 and other candidates have yet to demonstrate human efficacy, and a disappointing readout could sharply reset expectations.
- Cash burn and dilution: With a cash runway estimated into the first half of 2027, additional equity raises could pressure the share price.
- Rich valuation: The stock trades at a high price-to-book multiple and an elevated price-to-sales ratio relative to its minimal revenue, leaving little margin for error.
- Concentration risk: The story hinges on a small number of early-stage programs, making it vulnerable to any single clinical setback.
Technical Picture
The stock's 52-week low near $2.24 and high near $12.55 define a wide trading range following a powerful 2026 rally. The $12–$13 zone, which includes the recent 52-week high, represents a key resistance level that would likely need to be cleared before a move toward $15. On the downside, the $8–$9 area has served as a notable support level during recent consolidations. The $15 target sits above the stock's all-time-high region, meaning the move would require a fresh breakout rather than a return to prior levels.
What to Monitor Going Forward
Analyst price targets typically reflect a research horizon of about 12 months, though individual firms may apply different timelines and methodologies. Investors should monitor upcoming Phase 1 and Phase 2 data readouts for ABS-201 and ABS-101, quarterly earnings and cash-position updates, any further analyst target revisions, and whether strategic partners such as Eli Lilly or AMD deepen their involvement. Regulatory milestones and sector-wide sentiment toward AI drug discovery also matter.
Final Thoughts
Can Absci Corporation (ABSI) reach $15? The target is a legitimate average of verified analyst price targets, and it sits roughly 55% above recent trading levels. The strongest supports are clinical momentum, strategic backing from Eli Lilly and AMD, and a wave of upward target revisions. The principal obstacles are the absence of human efficacy data, ongoing losses, and a valuation that leaves little room for disappointment. With targets spanning $10 to $20, analysts themselves disagree sharply about how much the pipeline is worth. Reaching $15 would require clinical success and sustained investor conviction; it is a possibility, not a forecast. Watch the next data readouts, cash updates, and analyst revisions for the clearest signal of direction.
Exploring Tickeron’s AI Daily Buy/Sell Signals
In my own workflow I frequently review Tickeron’s AI Daily Buy/Sell Signals to stay on top of technical shifts in volatile names like this one. The tool applies AI to thousands of stocks and ETFs, delivering Buy, Sell, or Hold signals that help spot changing conditions without constant manual screening. It has become a useful complement when tracking clinical-stage stories that can move quickly on data releases.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ABSI sees its Stochastic Oscillator ascending out of oversold territory
On November 09, 2026, the Stochastic Oscillator for ABSI moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 60 instances where the indicator left the oversold zone. In 59 of the 60 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
ABSI moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ABSI crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 20 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +15.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABSI advanced for three days, in 242 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 141 of 175 cases where ABSI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABSI as a result. In 85 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for ABSI turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 42 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
ABSI broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ABSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.091) is normal, around the industry mean (3.498). P/E Ratio (-12.873) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (769.231) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement